NCT03829007 - PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 15, 2019

Primary Completion Date

December 17, 2020

Study Completion Date

December 9, 2021

Conditions

Head and Neck Cancer

Interventions

DIAGNOSTIC_TEST

PD-L1 imaging

89Zr-durvalumab injection followed by a PET/CT scan 5 days after injection

DRUG

Durvalumab

Durvalumab treatment is initiated after the PET/CT scan in a fixed dose of 1500 mg iv q4w

Trial Locations (4)

Amsterdam UMC, Amsterdam

UMC Groningen, Groningen

Leiden UMC, Leiden

Radboudumc, Nijmegen